


Supplementary Material – Figures and Tables

Supplementary Figure 1.



Supplementary Figure 1. Study schematic illustrating patients from SPSS included in this analysis after linkage to ANRESIS.

Supplementary Table 1

Supplementary Table 1. Number of patients in each risk group at each hospital.

| | Patient group | | | | | Total |
|-----------------|------------------------------------|------------------------------------|----------------------------------|--------------------------------------|--------------------------|---------------------|
| | group1 - neonatal sepsis CAI | group2 - neonatal sepsis HAI | group3 - CAI healthy children | group4 - CAI comorbidity children | group5 - HAI children | |
| Hospital | | | | | | |
| Hospital 1 | 10 (18%) | 13 (23%) | 26 (46%) | 7 (12%) | 0 (0%) | 56 (100%) |
| Hospital 2 | 11 (12%) | 15 (17%) | 34 (38%) | 20 (22%) | 9 (10%) | 89 (100%) |
| Hospital 3 | 26 (16%) | 18 (11%) | 52 (32%) | 44 (27%) | 24 (15%) | 164 (100%) |
| Hospital 4 | 7 (12%) | 16 (28%) | 24 (42%) | 9 (16%) | 1 (1.8%) | 57 (100%) |
| Hospital 5 | 1 (1.3%) | 29 (36%) | 13 (16%) | 15 (19%) | 22 (28%) | 80 (100%) |
| Hospital 6 | 22 (13%) | 59 (34%) | 33 (19%) | 31 (18%) | 29 (17%) | 174 (100%) |
| Hospital 7 | 12 (14%) | 12 (14%) | 38 (46%) | 12 (14%) | 9 (11%) | 83 (100%) |
| Hospital 8 | 7 (14%) | 42 (86%) | 0 (0%) | 0 (0%) | 0 (0%) | 49 (100%) |
| Hospital 9 | 9 (8.5%) | 20 (19%) | 50 (47%) | 16 (15%) | 11 (10%) | 106 (100%) |
| Hospital 10 | 17 (7.6%) | 24 (11%) | 58 (26%) | 59 (26%) | 66 (29%) | 224 (100%) |
| Total | 122 (11%) | 248 (23%) | 328 (30%) | 213 (20%) | 171 (16%) | 1,082 (100%) |

Supplementary Table 2

Supplementary Table 2. Overall summary of all pathogens isolated in the 10 study hospitals included in this analysis.


| Pathogen | Number | Proportion |
|-----------------------------------|--------|------------|
| Escherichia coli | 231 | 0.21 |
| Coagulase-negative Staphylococcus | 178 | 0.16 |
| Staphylococcus aureus | 172 | 0.16 |
| Streptococcus pneumoniae | 116 | 0.11 |
| Viridans group Streptococcus | 69 | 0.06 |
| Klebsiella pneumoniae | 42 | 0.04 |
| Streptococcus agalactiae | 46 | 0.04 |
| Streptococcus pyogenes | 41 | 0.04 |
| Enterococcus faecalis | 35 | 0.03 |
| Enterobacter cloacae | 26 | 0.02 |
| Haemophilus spp. | 18 | 0.02 |
| Neisseria meningitidis | 17 | 0.02 |
| Citrobacter spp. | 7 | 0.01 |
| Enterococcus faecium | 6 | 0.01 |
| Klebsiella oxytoca | 13 | 0.01 |
| Pseudomonas aeruginosa | 11 | 0.01 |
| Salmonella spp. | 9 | 0.01 |
| Serratia spp. | 6 | 0.01 |
| Acinetobacter spp. | 3 | 0.00 |
| Campylobacter jejuni | 1 | 0.00 |
| Enterobacter aerogenes | 2 | 0.00 |
| Enterobacter spp. | 3 | 0.00 |
| Enterococcus species | 5 | 0.00 |
| Fusobacterium spp. | 5 | 0.00 |
| Gemella species | 1 | 0.00 |
| Granulicatella adiacens | 1 | 0.00 |
| Group C Streptococcus | 2 | 0.00 |
| Kingella kingae | 1 | 0.00 |
| Listeria monocytogenes | 4 | 0.00 |
| Moraxella catarrhalis | 2 | 0.00 |
| Morganella morganii | 1 | 0.00 |
| Neisseria spp. | 5 | 0.00 |
| Proteus mirabilis | 2 | 0.00 |
| Stenotrophomonas maltophilia | 1 | 0.00 |

Supplementary Figure 2



Supplementary Figure 2. Pathogen distribution by risk group at each hospital.

Supplementary Figure 3.



Supplementary Figure 3. Pathogen distribution by hospital for each risk group.

Supplementary Table 3

Supplementary Table 3. Coverage probability estimates and 95% credible intervals for each regimen of interest at each hospital.

| Centre | Amoxicillin +Gentamicin | Amoxicillin/ clavulanic acid | Amoxicillin/ clavulanic acid +Gentamicin | Cefepime | Ceftriaxone | Ceftazidime +Amikacin | Piperacillin/ tazobactam | Meropenem |
|---------------------------------------|----------------------------|------------------------------------|--|------------------|------------------|--------------------------|-----------------------------|------------------|
| Coverage probability (95% CrI) | | | | | | | | |
| Hospital 1 | 0.91 (0.84-0.97) | 0.82 (0.68-0.91) | 0.88 (0.8-0.94) | 0.82 (0.71-0.91) | 0.81 (0.68-0.92) | 0.56 (0.44-0.67) | 0.86 (0.77-0.93) | 0.86 (0.74-0.94) |
| Hospital 2 | 0.87 (0.79-0.93) | 0.71 (0.62-0.79) | 0.83 (0.75-0.9) | 0.72 (0.62-0.8) | 0.75 (0.66-0.84) | 0.58 (0.48-0.68) | 0.72 (0.62-0.81) | 0.76 (0.65-0.85) |
| Hospital 3 | 0.81 (0.74-0.88) | 0.68 (0.59-0.76) | 0.83 (0.74-0.89) | 0.74 (0.65-0.81) | 0.76 (0.67-0.83) | 0.49 (0.42-0.57) | 0.76 (0.65-0.83) | 0.83 (0.75-0.9) |
| Hospital 4 | 0.79 (0.69-0.88) | 0.63 (0.51-0.74) | 0.77 (0.67-0.86) | 0.75 (0.64-0.84) | 0.74 (0.63-0.83) | 0.48 (0.37-0.59) | 0.63 (0.5-0.76) | 0.77 (0.66-0.86) |
| Hospital 5 | 0.57 (0.46-0.67) | 0.41 (0.31-0.51) | 0.57 (0.46-0.68) | 0.52 (0.41-0.61) | 0.51 (0.4-0.61) | 0.46 (0.35-0.56) | 0.54 (0.42-0.65) | 0.53 (0.42-0.63) |
| Hospital 6 | 0.73 (0.67-0.79) | 0.59 (0.53-0.66) | 0.73 (0.66-0.78) | 0.66 (0.59-0.73) | 0.64 (0.57-0.7) | 0.51 (0.44-0.58) | 0.65 (0.58-0.72) | 0.69 (0.62-0.76) |
| Hospital 7 | 0.86 (0.78-0.92) | 0.67 (0.57-0.76) | 0.84 (0.76-0.91) | 0.76 (0.66-0.84) | 0.76 (0.67-0.83) | 0.64 (0.54-0.73) | 0.72 (0.62-0.82) | 0.79 (0.69-0.86) |
| Hospital 8 | 0.59 (0.48-0.71) | 0.58 (0.45-0.7) | 0.65 (0.52-0.76) | 0.63 (0.51-0.75) | 0.58 (0.45-0.7) | 0.51 (0.38-0.63) | 0.63 (0.49-0.75) | 0.63 (0.51-0.75) |
| Hospital 9 | 0.87 (0.8-0.93) | 0.77 (0.69-0.85) | 0.88 (0.82-0.93) | 0.78 (0.7-0.85) | 0.78 (0.7-0.85) | 0.51 (0.42-0.61) | 0.8 (0.72-0.88) | 0.82 (0.75-0.89) |
| Hospital 10 | 0.84 (0.79-0.89) | 0.72 (0.67-0.78) | 0.84 (0.79-0.88) | 0.72 (0.63-0.79) | 0.76 (0.7-0.81) | 0.58 (0.51-0.64) | 0.8 (0.75-0.85) | 0.82 (0.76-0.86) |

Supplementary Table 4.

Supplementary Table 4. Coverage probability estimates and 95% credible intervals for each regimen of interest for each patient risk group.

| Risk Group | Amoxicillin +Gentamicin | Amoxicillin/ clavulanic acid | Amoxicillin/ clavulanic acid +Gentamicin | Cefepime | Ceftriaxone | Ceftazidime +Amikacin | Piperacillin/ tazobactam | Meropenem |
|--------------------------------------|----------------------------|---------------------------------|--|------------------|------------------|--------------------------|-----------------------------|------------------|
| Coverage pobability (95% CrI) | | | | | | | | |
| group1 - neonatal sepsis CAI | 0.87 (0.81-0.92) | 0.75 (0.68-0.82) | 0.87 (0.81-0.92) | 0.84 (0.77-0.9) | 0.81 (0.74-0.87) | 0.57 (0.48-0.65) | 0.81 (0.74-0.87) | 0.87 (0.81-0.93) |
| group2 - neonatal sepsis HAI | 0.63 (0.57-0.69) | 0.47 (0.41-0.53) | 0.63 (0.57-0.69) | 0.53 (0.47-0.59) | 0.52 (0.46-0.57) | 0.55 (0.49-0.61) | 0.56 (0.5-0.63) | 0.53 (0.47-0.59) |
| group3 - CAI healthy children | 0.92 (0.89-0.95) | 0.85 (0.81-0.89) | 0.9 (0.86-0.93) | 0.87 (0.83-0.91) | 0.91 (0.88-0.94) | 0.4 (0.34-0.45) | 0.88 (0.84-0.92) | 0.93 (0.88-0.96) |
| group4 - CAI comorbidity children | 0.85 (0.8-0.89) | 0.69 (0.63-0.75) | 0.85 (0.8-0.9) | 0.77 (0.71-0.82) | 0.75 (0.69-0.81) | 0.59 (0.53-0.66) | 0.78 (0.72-0.84) | 0.81 (0.75-0.86) |
| group5 - HAI children | 0.78 (0.72-0.84) | 0.56 (0.49-0.64) | 0.8 (0.74-0.85) | 0.62 (0.54-0.69) | 0.62 (0.55-0.69) | 0.68 (0.61-0.74) | 0.69 (0.62-0.75) | 0.74 (0.67-0.8) |

Supplementary Table 5

Supplementary Table 5. Coverage probability estimates and 95% credible intervals for regimens of interest PLUS vancomycin at each hospital.

| Centre | Amoxicillin +Gentamicin + Vancomycin | Amoxicillin/ clavulanic acid + Vancomycin | Amoxicillin/ clavulanic acid +Gentamicin + Vancomycin | Cefepime + Vancomycin | Ceftriaxone + Vancomycin | Ceftazidime +Amikacin + Vancomycin | Piperacillin/ tazobactam + Vancomycin | Meropenem + Vancomycin |
|--------------------------------------|--|---|--|--------------------------|-----------------------------|--|---|---------------------------|
| Coverage pobability (95% CrI) | | | | | | | | |
| Hospital 1 | 0.91 (0.84-0.97) | 0.85 (0.76-0.92) | 0.88 (0.8-0.95) | 0.88 (0.79-0.95) | 0.88 (0.8-0.95) | 0.88 (0.8-0.95) | 0.87 (0.78-0.94) | 0.92 (0.83-0.97) |
| Hospital 2 | 0.92 (0.86-0.97) | 0.82 (0.75-0.88) | 0.88 (0.81-0.94) | 0.87 (0.79-0.92) | 0.9 (0.84-0.95) | 0.86 (0.79-0.92) | 0.85 (0.78-0.91) | 0.93 (0.87-0.97) |
| Hospital 3 | 0.9 (0.85-0.94) | 0.73 (0.67-0.8) | 0.87 (0.82-0.91) | 0.85 (0.8-0.9) | 0.86 (0.81-0.91) | 0.85 (0.8-0.9) | 0.85 (0.8-0.9) | 0.95 (0.91-0.98) |
| Hospital 4 | 0.91 (0.84-0.96) | 0.79 (0.69-0.88) | 0.89 (0.8-0.95) | 0.89 (0.81-0.95) | 0.89 (0.81-0.95) | 0.87 (0.79-0.94) | 0.88 (0.79-0.94) | 0.91 (0.83-0.96) |
| Hospital 5 | 0.88 (0.8-0.94) | 0.76 (0.67-0.84) | 0.87 (0.8-0.93) | 0.91 (0.83-0.96) | 0.9 (0.83-0.95) | 0.91 (0.85-0.96) | 0.91 (0.84-0.96) | 0.92 (0.86-0.97) |
| Hospital 6 | 0.94 (0.9-0.97) | 0.84 (0.79-0.89) | 0.93 (0.9-0.96) | 0.92 (0.88-0.96) | 0.91 (0.86-0.95) | 0.91 (0.86-0.94) | 0.92 (0.88-0.95) | 0.95 (0.92-0.98) |
| Hospital 7 | 0.93 (0.88-0.98) | 0.79 (0.7-0.87) | 0.91 (0.85-0.96) | 0.91 (0.84-0.96) | 0.9 (0.83-0.95) | 0.91 (0.84-0.96) | 0.88 (0.81-0.94) | 0.93 (0.87-0.97) |
| Hospital 8 | 0.93 (0.85-0.98) | 0.88 (0.78-0.95) | 0.93 (0.85-0.98) | 0.93 (0.86-0.98) | 0.9 (0.81-0.96) | 0.93 (0.85-0.98) | 0.93 (0.85-0.98) | 0.93 (0.85-0.98) |
| Hospital 9 | 0.93 (0.86-0.96) | 0.82 (0.74-0.89) | 0.9 (0.84-0.95) | 0.87 (0.8-0.93) | 0.88 (0.82-0.94) | 0.87 (0.8-0.92) | 0.87 (0.81-0.93) | 0.92 (0.86-0.96) |
| Hospital 10 | 0.92 (0.89-0.95) | 0.8 (0.75-0.85) | 0.9 (0.86-0.93) | 0.86 (0.76-0.92) | 0.88 (0.84-0.92) | 0.89 (0.85-0.93) | 0.88 (0.84-0.92) | 0.94 (0.9-0.97) |

Supplementary Table 6

Supplementary Table 6. Coverage probability estimates and 95% credible intervals for regimens of interest PLUS vancomycin for each risk group.

| Risk Group | Amoxicillin +Gentamicin + Vancomycin | Amoxicillin/ clavulanic acid + Vancomycin | Amoxicillin/ clavulanic acid +Gentamicin + Vancomycin | Cefepime + Vancomycin | Ceftriaxone + Vancomycin | Ceftazidime +Amikacin + Vancomycin | Piperacillin/ tazobactam + Vancomycin | Meropenem + Vancomycin |
|--------------------------------------|--------------------------------------|---|---|-----------------------|--------------------------|------------------------------------|---------------------------------------|------------------------|
| Coverage pobability (95% CrI) | | | | | | | | |
| group1 - neonatal sepsis CAI | 0.91 (0.86-0.95) | 0.8 (0.73-0.86) | 0.91 (0.86-0.95) | 0.9 (0.84-0.94) | 0.88 (0.82-0.93) | 0.9 (0.85-0.94) | 0.87 (0.82-0.92) | 0.93 (0.88-0.97) |
| group2 - neonatal sepsis HAI | 0.97 (0.94-0.98) | 0.86 (0.82-0.9) | 0.96 (0.93-0.98) | 0.96 (0.94-0.98) | 0.95 (0.92-0.97) | 0.96 (0.94-0.98) | 0.94 (0.91-0.97) | 0.97 (0.94-0.98) |
| group3 - CAI healthy children | 0.95 (0.93-0.97) | 0.87 (0.83-0.9) | 0.91 (0.87-0.93) | 0.9 (0.87-0.93) | 0.95 (0.92-0.97) | 0.87 (0.83-0.9) | 0.91 (0.87-0.93) | 0.96 (0.92-0.98) |
| group4 - CAI comorbidity children | 0.93 (0.89-0.96) | 0.8 (0.74-0.85) | 0.91 (0.87-0.94) | 0.91 (0.86-0.94) | 0.89 (0.85-0.93) | 0.91 (0.87-0.94) | 0.91 (0.87-0.94) | 0.94 (0.91-0.97) |
| group5 - HAI children | 0.9 (0.86-0.94) | 0.71 (0.64-0.77) | 0.89 (0.85-0.93) | 0.83 (0.76-0.89) | 0.82 (0.77-0.88) | 0.89 (0.85-0.93) | 0.85 (0.79-0.9) | 0.93 (0.89-0.97) |